Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | FAAH | O00519 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.50 |
| ▸ | RELA | Q04206 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.46 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.46 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2955127 | 1.00 | CYP1A2 (0.51) | CYP1A2KMT2AMEN1RAB9ASMN1; SMN2 | |
| SCHEMBL13044360 | 0.81 | KMT2A (0.53) | CYP1A2KMT2AMEN1RAB9ASMN1; SMN2 | |
| SCHEMBL13044340 | 0.79 | KMT2A (0.57) | CYP1A2KMT2AMEN1RAB9ASMN1; SMN2 | |
| SCHEMBL11928783 | 0.77 | CYP1A2 (0.53) | CYP1A2KMT2AMEN1RAB9ASMN1; SMN2 | |
| SCHEMBL6117537 | 0.77 | CYP1A2 (0.53) | CYP1A2KMT2AMEN1RAB9ASMN1; SMN2 | |
| SCHEMBL6117540 | 0.77 | CYP1A2 (0.53) | CYP1A2KMT2AMEN1RAB9ASMN1; SMN2 | |
| SCHEMBL9505213 | 0.75 | LMNA (0.48) | CYP1A2KMT2AMEN1RAB9ASMN1; SMN2 | |
| SCHEMBL29176913 | 0.75 | CYP1A2 (0.50) | CYP1A2KMT2AMEN1RAB9ASMN1; SMN2 | |
| SCHEMBL4390386 | 0.75 | GSK3B (0.58) | KMT2AMEN1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL6894576 | 0.73 | GAA (0.51) | KMT2AMEN1POLBGAAHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9601806-B2 | Redox shuttle additives for lithium-ion batteries | UCHICAGO ARGONNE, LLC (US) | 2017-03-21 | — | — | US | disclosed |
| US-9005822-B2 | Functional electrolyte for lithium-ion batteries | UCHICAGO ARGONNE, LLC (US) | 2015-04-14 | — | — | US | disclosed |
| US-20140255793-A1 | FUNCTIONAL ELECTROLYTE FOR LITHIUM-ION BATTERIES | UCHICAGO ARGONNE, LLC (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140234703-A1 | REDOX SHUTTLE ADDITIVES FOR LITHIUM-ION BATTERIES | UCHICAGO ARGONNE, LLC (US) | 2014-08-21 | — | — | US | disclosed |
| WO-2013032593-A2 | REDOX SHUTTLES FOR OVERCHARGE PROTECTION OF LITHIUM BATTERIES | UCHICAGO ARGONNE, LLC (US) | 2013-03-07 | — | — | WO | disclosed |
| US-7648801-B2 | Lithium battery with series-connected cells having a shuttle of 2,5-di-tert--butyl-1,4-dimethoxybenzene; limits the negative electrode potential to a value slightly above that of positive electrode maximum normal operating potential toprevent negative electrode from reaching a higher damaging one | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2010-01-19 | — | — | US | disclosed |
| EP-1756905-A2 | REDOX SHUTTLE FOR OVERDISCHARGE PROTECTION IN RECHARGEABLE LITHIUM-ION BATTERIES | 3M Innovative Properties Company (US) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005099025-A2 | REDOX SHUTTLE FOR OVERDISCHARGE PROTECTION IN RECHARGEABLE LITHIUM-ION BATTERIES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-10-20 | — | — | WO | disclosed |
| US-20050221168-A1 | Redox shuttle for overdischarge protection in rechargeable lithium-ion batteries | DAHN JEFFREY R | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140255793-A1 | FUNCTIONAL ELECTROLYTE FOR LITHIUM-ION BATTERIES | LAGE3, KCNE1, KCNB2 | CYP1A2 2639/4885KMT2A 1530/4885MEN1 2873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.